临床下一代测序的自动化与常规化专家共识

doi:10.3969/j.issn.0258-8021.2023.06.001

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (846 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The matured automatically and routinely detection methods have not been generated since the overdecadeapplication of next-generation sequencing (NGS) in clinical practice. This consensus is oriented to the disciplines and applications of clinical NGS testing and provided relevant advices of constructing automatically and routinely path of clinical NGS, which was based on the current clinical application states and combined related testing products, consensus specifications and actual clinical demands from domestic and abroad. The consensus aimed at spreading the application, and promoting the entire level and the efficiency of precision medical services of clinical NGS in China.

Key words： clinical genetic testing next-generation sequencing automatization

Received: 21 March 2023

PACS:

R318

Corresponding Authors: ^*E-mail: kangxxtt@sina.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Laboratory Medicine Engineering Branch of Chinese Society of Biomedical Engineering

Cite this article:

Laboratory Medicine Engineering Branch of Chinese Society of Biomedical Engineering. Chinese Expert Consensus on Automation and Routine Sequencing of Next-Generation Sequencing in Clinical Practice[J]. Chinese Journal of Biomedical Engineering, 2023, 42(6): 641-650.

URL:

http://cjbme.csbme.org/EN/10.3969/j.issn.0258-8021.2023.06.001 OR http://cjbme.csbme.org/EN/Y2023/V42/I6/641

[1] Bell CJ, Dinwiddie DL, Miller NA, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing[J]. Science Translational Medicine, 2011,3(65):44-46.
[2] Cottrell CE, Al-Kateb H, Bredemeyer AJ, et al. Validation of a Next-Generation Sequencing Assay for Clinical molecular oncology[J]. The Journal of Molecular Diagnostics, 2014,16(1):89-105.
[3] Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum[J]. Lancet, 1997,350(9076):485-487.
[4] Hicks JK, Howard R, Reisman P, et al. Integrating somatic and germline next-generation sequencing into routine clinical oncology practice[J]. JCO Precis Oncol, 2021, 20(5): 885-895.
[5] Zhong Y, Xu F, Wu J, et al. Application of next generation sequencing in laboratory medicine[J]. Annals of Laboratory Medicine, 2021,41(1):25-43.
[6] GB/T 33681 高通量基因测序样本预处理方法[S]. 2017.
[7] MacConaill LE, Van Hummelen P, Meyerson M, et al. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges[J]. Cancer Discovery, 2011,1(4):297-311.
[8] 赵初娴, 王健民, 李军民,等. 应用二代测序技术分析急性髓系白血病患者基因突变及其对预后的影响[J]. 中华医学杂志, 2019,99 (40): 3145-3151.
[9] 黄荷凤, 乔杰, 刘嘉茵等. 胚胎植入前遗传学诊断/筛查技术专家共识[J]. 中华医学遗传学杂志, 2018,35(2) :151-155.
[10] Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program [DB]. www.genome.gov/sequencingcostsdata, 2022-07-16/2022-12-22.
[11] Jiang F, Ren J, Chen F, et al. Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies[J]. BMC Med Genomics, 2012,5:57.
[12] 中国临床肿瘤学会肿瘤标志物专家委员会. 中国肿瘤驱动基因分析联盟. 二代测序技术在肿瘤精准医学诊断中的应用专家共识[J]. 中华医学杂志, 2018,98 (26): 2057-2065.
[13] Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment[J]. Genetics in Medicine, 2015,17(1):70-87.
[14] 徐艳文,黄国宁,孙海翔,等. 高通量基因测序植入前胚胎遗传学诊断和筛查技术规范(试行)[J]. 生殖医学杂志, 2017, 26(5): 391-396.
[15] 李进. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南 [M]. 北京:人民卫生出版社, 2019.
[16] 张文宏, 艾静文,曹清,等. 中国宏基因组学第二代测序技术检测感染病原体的临床应用专家共识[J]. 中华传染病杂志, 2020,9: 681-689.
[17] 黄辉, 顾卫红, 黄尚志, 等. 临床基因检测报告规范与基因检测行业共识探讨[J]. 中华医学遗传学杂志, 2018,35 (1): 1-8.
[18] 王剑, 顾卫红, 黄辉,等. 遗传病二代测序临床检测全流程规范化共识探讨(1)——遗传检测前流程[J]. 中华医学遗传学杂志, 2020, 37(3): 334-338.
[19] 黄尚志, 曾秀凤, 黄辉,等. 遗传病二代测序临床检测全流程规范化共识探讨(2)——样品采集处理及检测[J]. 中华医学遗传学杂志, 2020, 37(3): 339-344.
[20] 沈亦平, 黄颐, 汪亮等. 遗传病二代测序临床检测全流程规范化共识探讨(3)——数据分析流程[J]. 中华医学遗传学杂志, 2020, 37(3): 345-351.
[21] 黄辉, 沈亦平, 顾卫红,等. 遗传病二代测序临床检测全流程规范化共识探讨(4)——检测报告解读和遗传咨询[J]. 中华医学遗传学杂志, 2020, 37(3): 352-357.
[22] 中国耳聋基因筛查与诊断临床多中心研究协作组, 全国防聋治聋技术指导组. 遗传性耳聋基因筛查规范[J]. 中华医学杂志, 2021,101(2): 97-102.
[23] Cheng DT, Mitchell TN, Zehir A, et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT) [J]. The Journal of Molecular Diagnostics, 2015,17(3):251-264.
[24] 周建娅, 莫伟芳, 赵菁,等. 非小细胞肺癌患者EGFR基因突变的临床病理特征[J]. 中华医学杂志, 2014,94 (30): 2332-2336.
[25] 张静静, 李蒙, 汪铮,等. 与基因和家族遗传相关的间质性肺疾病[J]. 中华医学杂志, 2021,101(27) : 2175-2178.
[26] 陶悦, 傅启华, 莫茜. 病原宏基因组测序在新型冠状病毒检测中的应用与挑战[J]. 中华检验医学杂志, 2020,43(3): 217-220.
[27] Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics[J]. Lancet Infect Dis, 2020,20(9): e238-e244.
[28] Standl F, Jockel KH, Brune B, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics[J]. Lancet Infect Dis, 2021,21(4):e77.
[29] 白莹, 李双, 宗亚楠,等. 杜氏/贝氏肌营养不良症433个家系的基因突变分析[J]. 中华医学杂志, 2016,96(16) : 1261-1269.
[30] 李艳春, 陈忠. 构建血液恶性肿瘤基因检测体系 [J]. 中华医学杂志, 2019,99 (41): 3209-3215.
[31] Garraway LA. Genomics-driven oncology: framework for an emerging paradigm[J]. J Clin Oncol, 2013, 31(15):1806-1814.
[32] Hess JF, Kohl TA, Kotrová M, et al. Library preparation for next generation sequencing: a review of automation strategies[J]. Biotechnology Advances, 2020,41:107537.
[33] Lundin S, Stranneheim H, Pettersson E, et al. Increased throughput by parallelization of library preparation for massive sequencing[J]. PLoS ONE, 2010,5(4):e10029.
[34] Mardis E, McCombie W R. Automated library preparation for DNA sequencing[J]. Cold Spring Harbor Protocols, 2017,2017(3):t94631.
[35] Koboldt DC, Steinberg KM, Larson DE, et al. The next-generation sequencing revolution and its impact on genomics[J]. Cell, 2013,155(1):27-38.
[36] Head SR, Komori HK, LaMere SA, et al. Library construction for next-generation sequencing: overviews and challenges[J]. BioTechniques, 2014,56(2):61-77.
[37] 张瑞, 吴祁生, 李金明. 应重视血液肿瘤相关分子检测实验室人员队伍的建设[J]. 中华医学杂志, 2021,101(13) : 904-907.
[38] Reid JG, Carroll A, Veeraraghavan N, et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline[J]. BMC Bioinformatics, 2014,15(1):30.
[39] 康倩, 金鹏, 杨浪,等. 外周血游离DNA中Septin9基因甲基化在结直肠癌筛查中的意义[J]. 中华医学杂志, 2014,94 (48): 3839-3841.
[40] 中华人民共和国人类遗传资源管理条例[EB/OL]. https://www.gov.cn/zhengce/content/2019-06/10/content_5398829.htm?t=1645782270297. 2016-06-10/2023-03-21.
[41] 余晨, 中华人民共和国数据安全法[EB/OL]. http://www.npc.gov.cn/npc/c30834/202106/7c9af12f51334a73b56d7938-f99a788a.shtml,2021-06-10/2022-12-22.
[42] 王芳, 刘红星. 转录组测序促进血液肿瘤精准医疗和临床实践[J]. 中华医学杂志, 2021,101(13):899-903.